Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Fuji
US Department of Justice
US Army
Accenture
Dow
Daiichi Sankyo
Novartis
AstraZeneca
Baxter

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,358,986

« Back to Dashboard

Summary for Patent: 6,358,986
Title: Polymorphs of telmisartan
Abstract:The invention relates to polymorphs of 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimid-azol-2-yl)benzimidazol-1-ylmet hyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.
Inventor(s): Schneider; Heinrich (late of Ingelheim, DE)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:09/480,211
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,358,986

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim MICARDIS telmisartan TABLET;ORAL 020850-003 Apr 4, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim MICARDIS telmisartan TABLET;ORAL 020850-001 Nov 10, 1998 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim MICARDIS telmisartan TABLET;ORAL 020850-002 Nov 10, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162-001 Nov 17, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim MICARDIS HCT hydrochlorothiazide; telmisartan TABLET;ORAL 021162-002 Nov 17, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,358,986

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 01 921Jan 19, 1999

Non-Orange Book US Patents Family Members for Patent 6,358,986

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,410,742 Polymorphs of telmisartan ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,358,986

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia 10202001 ➤ Subscribe
Slovenia 1144386 ➤ Subscribe
Saudi Arabia 584 ➤ Subscribe
Serbia 50044 ➤ Subscribe
Yugoslavia 51101 ➤ Subscribe
Portugal 1144386 ➤ Subscribe
Poland 211829 ➤ Subscribe
Poland 349425 ➤ Subscribe
Peru 13622000 ➤ Subscribe
New Zealand 513528 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
UBS
Cantor Fitzgerald
Novartis
Queensland Health
Fuji
Healthtrust
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot